Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050996 | 0.90 | EGLN1 (0.69) | EGLN1 | |
| SCHEMBL25278826 | 0.90 | EGLN1 (0.69) | EGLN1 | |
| SCHEMBL23562801 | 0.87 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL25934719 | 0.86 | EGLN1 (0.85) | EGLN1 | |
| Glycine SCHEMBL28393884 | 0.79 | EGLN1 (0.73) | EGLN1 | |
| SCHEMBL25233925 | 0.75 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL30458038 | 0.75 | EGLN1 (0.53) | EGLN1 | |
| SCHEMBL30457765 | 0.75 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL25282012 | 0.75 | EGLN1 (0.53) | EGLN1 | |
| SCHEMBL25232061 | 0.74 | EGLN1 (0.52) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118715015-A | Selective PHD1 inhibitor compounds, compositions and methods of use | 阿克比治疗有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN1, EGLN2 | EGLN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.